Our Businesses
Our Company
Share
Back to top
HIV/AIDS
-
We spoke to a scientist behind a treatment for the disease that was recently FDA-approved for adolescents ages 12 to 18 to learn how it could give them new hope.
-
Johnson & Johnson earned the #2 spot on the Access to Medicine Index, an important measurement of the company's longstanding commitment to make lifesaving medicine available and accessible to those who need it most.
-
Johnson & Johnson's Brian Woodfall, M.D., was working at a Vancouver clinic in the mid-1990s. That's where he met Tiko Kerr, who became one of the first patients to take the company's HIV medicines—and has thrived to this day. For National AIDS Awareness Month, watch as Kerr, Dr. Woodfall and fellow researcher Joss J. De Wet, M.D., reflect on how those treatments have saved lives and continue to evolve, in this moving video.
-
As the International AIDS Conference kicks off, learn how a new tool will help give this group greater power to prevent HIV on a monthly basis.
-
Normally, in this part of Uganda, medication is delivered by boat—a slow, difficult process. But now a new Johnson & Johnson-supported program is using drones that can serve 20 landing sites across five islands, reaching more than 3,700 people in a single day.
-
A relaunched Johnson & Johnson partnership will help ensure that many young patients get lifesaving access to HIV medicines. Meet a doctor in Kenya who explains why the program is so crucial.
-
For World AIDS Day, we look at the groundbreaking strides the company has made—and continues to make—toward a world without the disease.
-
The company is proud to have placed in the top 20 on the prestigious list for its commitment to innovation, dedication to social responsibility and the quality of its products, among other noteworthy attributes—all in the face of a global pandemic.
-
The Access to Medicine Index, a ranking of pharmaceutical companies' work to distribute medications to low- and middle-income countries, just named Johnson & Johnson #3 on its biennial list, underscoring the company's deep history of ensuring people in underserved communities receive the treatments they need.
-
A potential COVID-19 vaccine. Passionate efforts toward achieving racial and social justice. Smarter, more sustainable product packaging. These are just a few of the resolutions company change makers are aiming to bring to light this year—and they're already hard at work on them.
-
From epidemic masks that the company introduced during the Spanish flu pandemic to work it's doing today on an investigational COVID-19 vaccine, learn how the company has been at the forefront of safeguarding global public health for well over a century.
-
With its global Phase 3 clinical trial now fully enrolled with approximately 45,000 adult participants, we share the most up-to-date information about the single-dose investigational vaccine candidate.
-
The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
-
For World AIDS Day, three attendees of the virtual 2020 International AIDS Society Conference, including activist and actress Laverne Cox, talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.
-
Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.
